Matt Krebs
LightNews LightNews
banner
mattokrebs.bsky.social
Matt Krebs
@mattokrebs.bsky.social
210 followers 570 following 52 posts
BioCentury Inc. ( www.biocentury.com )

* Empowering Biopharma & Finance Execs | Travel Junkie & weekend warrior golfer

* Global Strategic Account Manager & Growth Team Sales Manager
Posts Replies Media Videos
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #cns #bloodbrainbarrier | Matt Krebs
BBB delivery tech is entering hyperspace? In just 2 weeks: • Eli Lilly and Company + ABL Bio Inc. ($2.6B deal, IGF1R platform) • Chiesi Group + AbbVie/Aliada (rare CNS disease) • Roche + Manifold...
www.linkedin.com
November 13, 2025 at 3:01 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#fda #crl #rtf | Matt Krebs
This one hurts. 😬 FDA slapping Biohaven with a CRL for its SCA drug--after collaborating on trial design and endpoint = OUCH!!! - Second rejection this week (see uniQure). - FDA now questioning ...
www.linkedin.com
November 7, 2025 at 12:47 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
October 2, 2025 at 11:13 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#als #parkinsons #mitochondria #neurodegeneration | Matt Krebs
⚡New Energy for ALS & Parkinson’s? Meet the other NRG. Not an energy drink. UK-based biotech advancing a novel mitochondrial approach in neurodegeneration. NRG Therapeutics closed a £50M Series B...
www.linkedin.com
October 2, 2025 at 4:35 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #keytruda #oncology | Matt Krebs
Alteogen rides Keytruda to the Major Leagues ⚾ Just days after FDA approval of Keytruda Qlex (Merck’s subQ pembrolizumab using Alteogen’s hyaluronidase tech), the EMA backed it too. That’s two big ...
www.linkedin.com
September 26, 2025 at 2:10 PM
mattokrebs.bsky.social
Is it just me, or seems like there are a bunch of “bots” leaving comments on BlueSky?
September 25, 2025 at 5:37 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #rockinhibitor #fibrosis | Matt Krebs
Remember Fraggle Rock? A scrappy bunch that, at the end of the day, got things done. They were working out of sight and underground. Well… meet AllRock Bio. Just out of stealth with a $50M Series...
www.linkedin.com
September 24, 2025 at 1:46 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
9 to 5 and 5 to 9 on the weeken | Matt Krebs
PERSONAL NOTE: What’s your ideal 9-5 / 5-9 kinda Saturday? Yesterday for me was a really good one, 'n one I hope to have more of. 🗻 Morning: - Hiked the Stanford Dish trail with my wife. ...
www.linkedin.com
September 23, 2025 at 4:32 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#immunology #bispecifics #harrypotter | Matt Krebs
When it comes to immune modulation… 2 targets > 1? Meet Dualitas Therapeutics. A newly launched biotech using proximity biology to create bispecific antibodies that bring two cell surface targets i...
www.linkedin.com
September 23, 2025 at 4:30 AM
mattokrebs.bsky.social
lnkd.in/p/gVXuSQ9i
#venturecapital #biotech #china | Matt Krebs
Scott Gottlieb Sounds Alarm on China Licensing Restrictions Why this matters for biopharma cos & financial firms: 💠 Squeezed pipeline: Chinese competition is already pushing U.S. investors to walk a...
lnkd.in
September 20, 2025 at 2:33 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #biopharma #cardiovascular #rnai #artificialintelligence | Matt Krebs
🚀 Corsera Health, launched with $50M to prevent cardiovascular disease BEFORE it starts. Biotech legends John Maraganore (Alnylam Pharmaceuticals) and Clive Meanwell (The Medicines Company.) are bac...
www.linkedin.com
September 4, 2025 at 4:53 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
March 2018 - HKEX Biotech Summit 2018 | Matt Krebs
I have great memories being in Hong Kong in March 2018 for the first HKEX Biotech Summit with my colleague Joshua Berlin Back then, Chapter 18A was more thesis than track record. A lot has happened ...
www.linkedin.com
September 1, 2025 at 10:54 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #venturecapital #lifesciences | Matt Krebs
🎶 “Carolina in my mind”... with venture funds and translational science. South Carolina just launched two new VC funds via MUSC, aiming to bridge its biotech “valley of death” and punch above its wei...
www.linkedin.com
August 29, 2025 at 1:14 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
#biotech #crossborder #biopharma | Matt Krebs
Are you factoring China into your BD&L roadmap? If not, BioCentury Inc.’s latest report gives some data and insights that could change your mind: 🔹 Deals now move at "China speed". 🔹202...
www.linkedin.com
August 23, 2025 at 3:22 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
It’s no secret that leadership teams at biotech cos are getting creative to survive--everything from partnering, fundraising, M&A, to selling off assets. | Matt Krebs
It’s no secret that leadership teams at biotech cos are getting creative to survive--everything from partnering, fundraising, M&A, to selling off assets. Knowing who has dry powder isn’t enough. In...
www.linkedin.com
August 17, 2025 at 11:55 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
Ready to take Steve Usdin’s "Master Class" on reimagining the FDA? | Matt Krebs
Ready to take Steve Usdin’s "Master Class" on reimagining the FDA? 🎓⚖️ ⚠️ This isn’t for everyone ⚠️ It’s for strategic thinkers. For current (and future) thought leaders in biopharma, policy, and ...
www.linkedin.com
August 15, 2025 at 3:57 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
True story: I was once an "illegal alien" detained in an airport 🗾 🏯 🈲 | Matt Krebs
True story: I was once an "illegal alien" detained in an airport 🗾 🏯 🈲 "Illegal Alien" was my official status for about 45 mins @ KIX. It was the early 2000s. I was in KIX (Osaka Airport) heading ...
www.linkedin.com
August 15, 2025 at 2:28 PM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
Can you imagine an FDA rebuilt from a blank page? | Matt Krebs
Can you imagine an FDA rebuilt from a blank page? I wonder if you can? Provocative? Yes. Necessary? You be the judge. My colleague Steve Usdin’s "Back to School 2025" (BioCentury Inc.) lays out a...
www.linkedin.com
August 13, 2025 at 5:46 PM
mattokrebs.bsky.social
1-min video on Series A financing analysis in BioCentury. www.linkedin.com/posts/mattkr...
Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. | Matt Krebs
Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. The problem? $100M+ rounds were throwing the numbers out of whack. They found D...
www.linkedin.com
August 10, 2025 at 1:55 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
This BioCentury Inc. | Matt Krebs
This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. https://lnkd.in/gcC-2nQZ
www.linkedin.com
August 10, 2025 at 1:54 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” | Matt Krebs posted on the topic | LinkedIn
A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” They were referring to our latest coverage on quantum computing, and why it matters now for biopharma lead...
www.linkedin.com
August 7, 2025 at 2:35 AM
mattokrebs.bsky.social
www.linkedin.com/posts/mattkr...
🎭 “Somebody stop me!” 🎭 | Matt Krebs posted on the topic | LinkedIn
🎭 “Somebody stop me!” 🎭 --masked biologics, breaking past old toxicity limits with new clinical momentum Tierney Baum, PhD (BioCentury Inc.) unveils her latest analysis on how masking platforms are ...
www.linkedin.com
August 7, 2025 at 2:34 AM
mattokrebs.bsky.social
🎡 Zoltar meets predictive pharmacology?

www.linkedin.com/posts/mattkr...
🎡 Zoltar meets predictive pharmacology? | Matt Krebs
🎡 Zoltar meets predictive pharmacology? [Full disclosure -- BIG was one of my favorite movies growing up!] My colleague Tierney Baum, PhD talks to Syndeio Biosciences on their CNS drug development...
www.linkedin.com
August 7, 2025 at 2:33 AM
mattokrebs.bsky.social
This BioCentury Inc. data will surprise you?

A look at private biopharma raising Seed and Series A rounds over past 9 years. www.linkedin.com/posts/mattkr...
This BioCentury Inc. | Matt Krebs
This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. https://lnkd.in/gcC-2nQZ
www.linkedin.com
August 7, 2025 at 2:31 AM
mattokrebs.bsky.social
Monty Python fans out here? www.linkedin.com/posts/mattkr...
Are you seeing a flurry of activity in endometriosis? | Matt Krebs
Are you seeing a flurry of activity in endometriosis? Despite this miss by Organon, I’m hearing growing investor interest. A.k.a. Endometriosis is coming up more often on calls I’m on with VCs/CVCs, ...
www.linkedin.com
July 5, 2025 at 3:43 AM